Drug used for menorrhagia may prevent postpartum hemorrhageA drug that is low cost and easy to administer may help prevent maternal deaths, according to results of a randomized clinical trial. Plus: Does air pollution affect menstrual regularity? Also: According to a statement published by the American Heart Association (AHA), breast cancer patients may be at increased risk of cardiovascular disease (CVD).
Pharmacists on the Front Line in Treating Cardiac Disease
Pharmacists on the Front Line in Treating Cardiac DiseaseWhen it comes to cardiac disease, pharmacists in all practice settings can make a difference.
Three top criticisms against CMS’ overall hospital star ratingsStakeholders say CMS’ hospital overall star ratings are biased and can unfairly damage the reputations of good hospitals.
Entresto may prevent death in some heart failure patientsTimely and broad use of Entresto could prevent or postpone more than 28,000 US deaths per year among HFrEF patients, according to research in JAMA Cardiology.
T2DM and CVD: Monitoring by pharmacists empowers patientsType 2 diabetes is associated with a two- to four-fold increase in the risk of CVD. Pharmacists can monitor and manage the risk factors.
A low-fat, plant-based diet may help obese children lower heart disease riskA low-fat plant-based vegan diet may help obese children lower their risk of heart disease, finds a new study from Cleveland Clinic.
[BLOG]: AHA Scientific Sessions 2014: Where do the PCSK9s fit in the post-IMPROVE-IT world? A “modest” proposalThis year, the American Heart Association (AHA) Scientific Sessions were held in Chicago, Illinois, from November 15 to 19. Of all of the late-breaking clinical trials presented at AHA 2014, the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) study of Merck’s low-density lipoprotein cholesterol (LDL-C)-reducing drugs—the statin, Zocor (simvastatin), and the fixed-dose combination, Vytorin (ezetimibe/simvastatin)—stole the show.
AHA: Rivaroxaban linked to fewer hospitalization days compared to warfarin in NVAF patientsOnce-daily rivaroxaban (Xartelto, Janssen) is associated with significantly fewer hospitalization days and outpatient visits compared to warfarin in patients with nonvalvular atrial fibrillation (NVAF), according to data presented at the American Heart Association (AHA) 2014 Scientific Sessions in Chicago.
AHA issues stroke guidelines for womenFor the first time, guidelines have been developed for preventing stroke in women.
AMA says the physician exodus to hospitals overratedRecent reports claiming that physicians are moving swiftly away from private practices into hospital employment are exaggerated, according to a report released by the American Medical Association (AMA).